Autologous cd34+ enriched cell fraction that contains cd34+ cells transduced with retroviral vector that encodes for the human ada cdna sequence
Strimvelis
Indication
Strimvelis is indicated for the treatment of patients with severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID), for whom no suitable human leukocyte antigen (HLA)-matched related stem cell donor is available (see section 4.2 and section 4.4).
In other countries
The same active substances on other registers, the same brand first.
National listings
The national registers that list this EU medicine.
Documents
The official texts, at the regulator.